Telix and Radboud seal clinical collaboration agreement
MELBOURNE, Australia & NIJMEGAN, Netherlands—Telix Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals, or molecularly-targeted radiation (MTR), in March announced a clinical collaboration with Radboud University Medical Center (Radboudumc).
Telix is developing 89Zr-girentuximab (TLX-250) for the purpose of imaging clear cell renal cell cancer (ccRCC) with positron emission tomography (PET). Radboudumc and Telix will collaborate on several clinical projects in relation to TLX-250, including leading the pre-Phase 3 bridging/dosimetry study for TLX-250, participating as a key adviser for the Phase 3 study, as well as the IMPACT-RCC study (NCT02228954) to better understand how molecular imaging can be used to measure therapeutic treatment response in metastatic kidney cancer.
“Radboudumc has been a clinical leader in the use of 89Zr-girentuximab (TLX-250) in the clinic and their patient experience underpins much of the confidence we have in the imaging agent, particularly the change in isotope to a radiometal for superior image quality, sensitivity and patient convenience,” said Dr. Andreas Kluge, co-founder and chief medical officer of Telix. “We have worked closely with Radboudumc as part of activating our clinical activity for TLX-250 in Europe.”
Prof. Peter Mulders, chairman of the Department of Urology at Radboudumc noted, “We are pleased to be working with Telix to progress this very important technology from a clinical perspective. This international collaboration lays the foundation for the completion of product development of 89Zr-girentuximab and we are delighted to be part of bringing this technology to renal cancer patients in the Netherlands and beyond.”
As part of the collaboration, Telix will fund a clinical fellowship position at the Department of Radiology and Nuclear Medicine of the Radboudumc to oversee the various activities around the collaboration. The Radboudumc Technology Center imaging facility will also be a key partner, with its cutting-edge technology and expertise for preclinical and clinical imaging.